NASDAQ:ZYXI Zynex (ZYXI) Stock Price, News & Analysis → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free ZYXI Stock Alerts $9.59 -0.05 (-0.52%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$9.55▼$9.7250-Day Range$9.35▼$12.5652-Week Range$6.88▼$13.77Volume71,600 shsAverage Volume206,861 shsMarket Capitalization$304.67 millionP/E Ratio41.70Dividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zynex alerts: Email Address Zynex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside87.7% Upside$18.00 Price TargetShort InterestBearish33.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth84.31%From $0.51 to $0.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 starsMedical Sector413th out of 903 stocksElectromedical Equipment Industry6th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingZynex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZynex has only been the subject of 1 research reports in the past 90 days.Read more about Zynex's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted33.82% of the float of Zynex has been sold short.Short Interest Ratio / Days to CoverZynex has a short interest ratio ("days to cover") of 36.6, which indicates bearish sentiment.Change versus previous monthShort interest in Zynex has recently decreased by 2.19%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldZynex does not currently pay a dividend.Dividend GrowthZynex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYXI. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows3 people have added Zynex to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynex insiders have not sold or bought any company stock.Percentage Held by Insiders52.13% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.68% of the stock of Zynex is held by institutions.Read more about Zynex's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Zynex are expected to grow by 84.31% in the coming year, from $0.51 to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynex is 41.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.31.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynex is 41.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 110.35.Price to Book Value per Share RatioZynex has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About Zynex Stock (NASDAQ:ZYXI)Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Read More ZYXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYXI Stock News HeadlinesMay 10, 2024 | finance.yahoo.comHere's Why We Think Zynex, Inc.'s (NASDAQ:ZYXI) CEO Compensation Looks FairMay 9, 2024 | prnewswire.comZynex to Present at the RBC Capital Markets Global Healthcare ConferenceMay 7, 2024 | prnewswire.comZynex Executives Recognized Among Top 25 in Medical TechnologyMay 2, 2024 | finance.yahoo.comZynex, Inc. (NASDAQ:ZYXI) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comZynex Inc (ZYXI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Seizing ...April 30, 2024 | msn.comZYXI Stock Earnings: Zynex Misses Revenue for Q1 2024April 30, 2024 | finance.yahoo.comZynex Inc (ZYXI) Q1 2024 Earnings: Revenue Meets Expectations, EPS Falls ShortApril 30, 2024 | prnewswire.comZynex Reports First Quarter 2024 Financial ResultsApril 29, 2024 | markets.businessinsider.comWhat Wall Street expects from Zynex's earningsApril 28, 2024 | finance.yahoo.comZynex, Inc. (ZYXI)April 26, 2024 | finance.yahoo.comInvesting in Zynex (NASDAQ:ZYXI) five years ago would have delivered you a 82% gainApril 18, 2024 | prnewswire.comZynex Sets First Quarter 2024 Earnings CallApril 2, 2024 | investorplace.com3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation?April 2, 2024 | prnewswire.comZynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition AwardMarch 30, 2024 | finance.yahoo.comWith 51% ownership, Zynex, Inc. (NASDAQ:ZYXI) insiders have a lot riding on the company's futureMarch 16, 2024 | finance.yahoo.comZYXI Aug 2024 20.000 callMarch 15, 2024 | wsj.comZynex Inc.March 3, 2024 | finance.yahoo.comZynex Full Year 2023 Earnings: Misses ExpectationsMarch 2, 2024 | seekingalpha.comZynex, Inc. (ZYXI) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comZynex, Inc. (NASDAQ:ZYXI) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comHere's what to expect from Zynex's earningsMarch 1, 2024 | finance.yahoo.comZynex Price Target Raised by RBC Capital, HC Wainwright AnalystsFebruary 29, 2024 | benzinga.comZynex: Q4 Earnings InsightsFebruary 29, 2024 | msn.comZynex GAAP EPS of $0.04 misses by $0.13, revenue of $47.28M misses by $8.34MFebruary 29, 2024 | finance.yahoo.comZynex Inc (ZYXI) Reports 17% Revenue Growth in FY 2023, Announces New $20 Million Stock ...See More Headlines Receive ZYXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today6/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:ZYXI CUSIPN/A CIK846475 Webwww.zynex.com Phone(303) 703-4906FaxN/AEmployees1,100Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$21.00 Low Stock Price Target$15.00 Potential Upside/Downside+87.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.23 Trailing P/E Ratio41.70 Forward P/E Ratio18.80 P/E GrowthN/ANet Income$9.73 million Net Margins4.33% Pretax Margin5.82% Return on Equity16.34% Return on Assets5.76% Debt Debt-to-Equity Ratio1.76 Current Ratio3.58 Quick Ratio2.87 Sales & Book Value Annual Sales$188.68 million Price / Sales1.61 Cash Flow$0.41 per share Price / Cash Flow23.30 Book Value$1.36 per share Price / Book7.05Miscellaneous Outstanding Shares31,775,000Free Float15,211,000Market Cap$304.72 million OptionableOptionable Beta0.61 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Thomas Sandgaard (Age 65)Founder, President, CEO & Chairman Comp: $992.83kMr. Daniel J. Moorhead (Age 52)Chief Financial Officer Comp: $472.61kMs. Anna Lucsok (Age 37)Chief Operating Officer Comp: $400.84kMr. Steve FoxVice President Of SalesMr. Donald GreggPresident of Zynex Monitoring SolutionsMr. Neil FrieryPresident & COO of Zynex Monitoring Solutions, Inc.More ExecutivesKey CompetitorsBioLife SolutionsNASDAQ:BLFSAxoGenNASDAQ:AXGNOutset MedicalNASDAQ:OMSemler ScientificNASDAQ:SMLREdap TmsNASDAQ:EDAPView All CompetitorsInsiders & InstitutionsHancock Whitney CorpBought 6,566 shares on 5/17/2024Ownership: 0.104%Walleye Trading LLCSold 4,200 shares on 5/17/2024Ownership: 0.000%Janus Henderson Group PLCSold 76,126 shares on 5/16/2024Ownership: 0.091%BOKF NABought 19,662 shares on 5/15/2024Ownership: 0.062%Vanguard Group Inc.Bought 6,097 shares on 5/10/2024Ownership: 3.737%View All Insider TransactionsView All Institutional Transactions ZYXI Stock Analysis - Frequently Asked Questions Should I buy or sell Zynex stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZYXI shares. View ZYXI analyst ratings or view top-rated stocks. What is Zynex's stock price target for 2024? 2 Wall Street analysts have issued 12 month target prices for Zynex's stock. Their ZYXI share price targets range from $15.00 to $21.00. On average, they anticipate the company's share price to reach $18.00 in the next year. This suggests a possible upside of 87.7% from the stock's current price. View analysts price targets for ZYXI or view top-rated stocks among Wall Street analysts. How have ZYXI shares performed in 2024? Zynex's stock was trading at $10.89 at the beginning of the year. Since then, ZYXI shares have decreased by 11.9% and is now trading at $9.59. View the best growth stocks for 2024 here. How were Zynex's earnings last quarter? Zynex, Inc. (NASDAQ:ZYXI) released its earnings results on Thursday, February, 29th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.17 by $0.13. The business earned $47.28 million during the quarter, compared to the consensus estimate of $54.53 million. Zynex had a trailing twelve-month return on equity of 16.34% and a net margin of 4.33%. The business's quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter last year, the business posted $0.20 earnings per share. What guidance has Zynex issued on next quarter's earnings? Zynex updated its second quarter 2024 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of 0.080- for the period, compared to the consensus estimate of 0.070. The company issued revenue guidance of $52.0 million-, compared to the consensus revenue estimate of $53.1 million. What is Thomas Sandgaard's approval rating as Zynex's CEO? 81 employees have rated Zynex Chief Executive Officer Thomas Sandgaard on Glassdoor.com. Thomas Sandgaard has an approval rating of 87% among the company's employees. Who are Zynex's major shareholders? Zynex's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.74%), Rice Hall James & Associates LLC (0.75%), Bridge City Capital LLC (0.58%), Congress Asset Management Co. MA (0.37%), LSV Asset Management (0.34%) and Janney Montgomery Scott LLC (0.28%). Insiders that own company stock include Anna Lucsok, Daniel J Moorhead and Thomas Sandgaard. View institutional ownership trends. How do I buy shares of Zynex? Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZYXI) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zynex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.